通化东宝：利拉鲁肽注射液获巴西GMP证书

Core Insights - Tonghua Dongbao's liraglutide injection has received GMP certification from Brazil's ANVISA, marking a significant step in the product's compliance process for the Latin American market [1] - The GMP certification is recognized globally as a high-standard quality management system, indicating that the product meets rigorous international standards [1] - The increasing prevalence of diabetes in emerging markets like Latin America creates a growing demand for high-quality biopharmaceuticals, positioning Tonghua Dongbao's product as a valuable treatment option for local patients [1] Company Developments - Since the partnership with Sinovac Biotech, Tonghua Dongbao has efficiently advanced the overseas registration and GMP auditing of liraglutide injection, achieving multiple regulatory milestones in Latin America [2] - The product has already received GMP certification in Colombia and approval for market launch in Peru, establishing a strong presence in the Latin American market [2] - The company is accelerating its international strategy and enhancing collaboration with Sinovac to expedite the registration and commercialization of liraglutide injection in target markets [2]